EIDD-2801 to EIDD-1931 Equimolar Dose Conversion: Derivation and Peer-Reviewed Basis of the 1.27 Molar Weight Ratio
Authors/Creators
Description
This technical note provides a transparent, source-referenced derivation of the molar weight conversion factor (1.27) used to calculate equimolar doses of EIDD-1931 (N4-hydroxycytidine, NHC) from established EIDD-2801 (molnupiravir) dosing schedules. The factor is a standard stoichiometric ratio derived from the confirmed molecular weights of EIDD-2801 (329.31 g/mol) and EIDD-1931 (259.22 g/mol), verified via PubChem (NIH) and corroborated by peer-reviewed publications in high-impact journals. The document explains the prodrug–active metabolite relationship, the esterase-mediated hydrolysis mechanism, and provides first-principles verification of both molecular weights using IUPAC atomic weights. Prepared to support accurate equimolar dosing calculations in feline medicine, with application to conditions including feline infectious peritonitis (FIP), feline calicivirus (FCV), feline gingivitis, and feline chronic gingivostomatitis (FCGS).
Files
NHC_Equimolar_Dose_Conversion_Reference.pdf
Files
(93.7 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:e7d89fb25307b875759f9daf7c50f833
|
93.7 kB | Preview Download |
Additional details
References
- National Center for Biotechnology Information, NIH. PubChem Compound Summary. EIDD-2801: CID 145996610. https://pubchem.ncbi.nlm.nih.gov/compound/145996610. EIDD-1931: CID 197020. https://pubchem.ncbi.nlm.nih.gov/compound/197020 [Accessed June 2026].
- Sheahan TP, Sims AC, Zhou S, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020;12(541):eabb5883. doi: 10.1126/scitranslmed.abb5883
- Painter WP, Holman W, Bush JA, et al. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob Agents Chemother. 2021;65(5):e02428-20. doi: 10.1128/AAC.02428-20
- Agostini ML, Pruijssers AJ, Chappell JD, et al. Small-molecule antiviral β-D-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J Virol. 2019;93(24):e01348-19. doi: 10.1128/JVI.01348-19
- FitzGerald R, Dickinson L, Else L, et al. Pharmacokinetics of beta-d-N4-hydroxycytidine, the parent nucleoside of prodrug molnupiravir, in nonplasma compartments of patients with severe acute respiratory syndrome coronavirus 2 infection. Clin Infect Dis. 2022;75(1):e525-e528. doi: 10.1093/cid/ciac199. PMC8992239.
- Meija J, Coplen TB, Berglund M, et al. Atomic weights of the elements 2013 (IUPAC Technical Report). Pure Appl Chem. 2016;88(3):265–291. doi: 10.1515/pac-2015-0305